Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
66.20    -1.80 (-2.65%)
Bid:
65.90
Ask:
66.70
Spread: 0.80 (1.214%)
Market Cap: £584.83m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Board changes

4 May 2018 07:00

RNS Number : 1008N
IP Group PLC
04 May 2018
 

FOR RELEASE ON

04 May 2018

 

IP Group plc - Board changes

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), the developer of intellectual property-based businesses, announces that Mike Humphrey has indicated that for personal reasons he wishes to retire and step down from his position as Non-executive Chairman and a director of the Company as soon as a suitable replacement can be recruited.

 

Mr Humphrey joined the Board of IP Group in October 2011 as a non-executive Director and became Non-executive Chairman in March 2015. He has served as Senior Independent Director, Chairman of the Remuneration Committee and is currently Chairman of the Nomination Committee and a member of the Remuneration Committee.

 

In addition, IP Group announces that Heejae Chae has been appointed as Non-executive Director with immediate effect while Professor Lynn Gladden has indicated that she will be stepping down from her role as Non-executive Director on or prior to 31 December 2018. Professor Gladden has been appointed to the role of Executive Chairman of the Engineering and Physical Sciences Research Council (EPSRC) with effect from 1st of October and, as such, will need to step down from her role at IP Group to avoid any potential conflict of interests.

 

Mr Chae is currently Chief Executive of AIM-listed Scapa Group plc, a global supplier of products for healthcare and industrial markets. Prior to joining Scapa, Mr Chae was Group Chief Executive of Volex Group plc. He was previously the Group General Manager, Radio Frequency Worldwide, for Amphenol Corporation. He spent the early part of his career in finance at The Blackstone Group and Credit Suisse First Boston before moving into industry. Mr Chae has degrees in Economics and Engineering from Columbia University and an MBA from Harvard University. Mr Chae also serves on the Board of Overseers at Boston Children's Hospital and is an Advisory Council Member at Columbia University.

 

Alan Aubrey, Chief Executive of IP Group, said: "Mike has made a significant contribution to the growth of IP Group during his tenure. On behalf of the Board and all of the Company's staff, I would like to thank Mike for his hard work and wise counsel over the years and to wish him well. I would also like to express my thanks to Lynn for her contribution over the last four years and I'm delighted to welcome Heejae Chae to the Board and look forward to working with him."

 

Mike Humphrey, Chairman, said: "Since joining IP Group, the Company has undergone a rapid period of growth which has seen a near ten-fold increase in the value of the portfolio as well as expansion into both the US and Australasia. It has been an honour to work alongside such a talented team and I am confident that the Group will go from strength to strength."

 

A further announcement will be made in due course once Mr Humphrey's replacement has been selected.

 

This announcement is made pursuant to Listing Rule 9.6.11R. There are no other details required to be disclosed under Listing Rule 9.6.13R. There are no further disclosures required under the Disclosure and Transparency Rules.

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Alan Aubrey, Chief Executive OfficerGreg Smith, Chief Financial OfficerLiz Vaughan-Adams, Communications

+44 (0) 20 7444 0050+44 (0) 20 7444 0062/+44 (0) 7979 853802

Charlotte Street Partners

Andrew Wilson

+44 (0) 7810 636995

Martha Walsh

+44 (0) 7876 245962

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.

For more information, please visit our website at www.ipgroupplc.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAVXLFBVEFXBBB
Date   Source Headline
19th Oct 20216:31 pmRNSTransaction in Own Shares
19th Oct 20217:00 amRNSTransaction in Own Shares
18th Oct 20217:00 amRNSTransaction in Own Shares
14th Oct 20216:27 pmRNSTransaction in Own Shares
13th Oct 20216:22 pmRNSTransaction in Own Shares
13th Oct 202111:36 amRNSDirector Declaration
13th Oct 20219:03 amRNSHolding(s) in Company
12th Oct 20216:20 pmRNSTransaction in Own Shares
12th Oct 20212:09 pmRNSDirector/PDMR Shareholding
12th Oct 20217:00 amRNSTransaction in Own Shares
11th Oct 20217:41 amRNSTransaction in Own Shares
8th Oct 20217:00 amRNSShare buyback programme
6th Oct 20217:00 amRNSBoard changes
5th Oct 20214:44 pmRNSHolding(s) in Company
30th Sep 20214:11 pmRNSTotal Voting Rights
30th Sep 20217:45 amRNSIP Group generates £84m from Oxford Nanopore IPO
27th Sep 202112:40 pmRNSDirector/PDMR Shareholding
23rd Sep 20213:57 pmRNSFurther re Scrip Dividend
16th Sep 20217:08 amRNSOxford Nanopore confirms ITF; MoU with Oracle
10th Sep 20215:21 pmRNSHolding(s) in Company
8th Sep 202110:53 amRNSDirector/PDMR Shareholding, SAYE scheme
19th Aug 202110:41 amRNSScrip Dividend Reference Price
12th Aug 20215:05 pmRNSDirector Declaration
5th Aug 20217:00 amRNSHalf-yearly results
27th Jul 20217:03 amRNSPortfolio company Artios Pharma raises $153m
22nd Jul 202111:30 amRNSNotice of Results
1st Jul 20217:00 amRNSTotal Voting Rights
28th Jun 20217:30 amRNSDirector/PDMR Shareholding
18th Jun 20219:52 amRNSDirector/PDMR Shareholding
17th Jun 20217:00 amRNSPortfolio company Apollo Therapeutics raises $145m
15th Jun 20218:00 amRNSFurther re Scrip Dividend
9th Jun 202111:29 amRNSResult of AGM
9th Jun 20217:00 amRNSAGM Statement
7th Jun 20217:00 amRNSPortfolio co Iksuda completes $42m financing round
28th May 20213:36 pmRNSDirector/PDMR Shareholding
28th May 202110:00 amRNSJoint venture with China Everbright to launch fund
27th May 20217:00 amRNSPortfolio co Pulmocide completes $92m Series C
26th May 20212:44 pmRNSUpdate on AGM
20th May 202110:01 amRNSScrip Dividend Reference Price
17th May 202112:44 pmRNSAdditional fair value gain of £20m
12th May 202112:08 pmRNSHolding(s) in Company
10th May 202111:15 amRNSInvestor webinars
6th May 20216:13 pmRNSNotice of AGM, Annual Report, Scrip Dividend
6th May 20215:55 pmRNSLTIP & DBSP awards; Director/PDMR shareholding
5th May 20217:00 amRNSPortfolio company Inivata acquired by NeoGenomics
5th May 20217:00 amRNSPortfolio company Kuur acquired by Athenex
4th May 20217:00 amRNSPortfolio company Oxford Nanopore raises £195m
7th Apr 202111:27 amRNSDirector/PDMR Shareholding
31st Mar 20219:15 amRNSHolding(s) in Company
30th Mar 20217:05 amRNSOxford Nanopore announces preparing for IPO in H2

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.